# Uwe Haberkorn

Source: https://nuclide.cc/people/uwe-haberkorn/  
Nuclide record `uwe-haberkorn` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.

## Summary

Uwe Haberkorn is Head of Nuclear Medicine at Heidelberg University Hospital and the German Cancer Research Center (DKFZ). His specialisms are nuclear medicine, FAP-targeted radiopharmaceuticals and theranostics, with a focus on the FAP and PSMA targets. His Heidelberg group invented the quinoline-based FAP inhibitor (FAPI) tracers, and his Journal of Nuclear Medicine paper reported 68Ga-FAPI PET/CT tracer uptake across 28 different kinds of cancer. The group also led early PSMA-617 and FAP-targeted radioligand therapy in humans, and his record links him to FAP-2286 and lutetium-177 vipivotide tetraxetan. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Head of Nuclear Medicine, Heidelberg University Hospital and DKFZ
- Specialisms: Nuclear medicine; FAP-targeted radiopharmaceuticals; Theranostics

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Haberkorn%20U%5BAuthor%5D%20FAPI

## Connected records

- isotopes: [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- technologies: [FAPI PET](https://nuclide.cc/technologies/fapi-pet/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [FAP](https://nuclide.cc/targets/fap/), [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [FAP-2286 (177Lu / 68Ga)](https://nuclide.cc/drugs/fap-2286/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- institutions: [European Association of Nuclear Medicine](https://nuclide.cc/institutions/eanm/), [Heidelberg University Hospital / NCT / DKFZ](https://nuclide.cc/institutions/heidelberg-nct/)
- journals: [Journal of Nuclear Medicine](https://nuclide.cc/journals/journal-of-nuclear-medicine/)
- ideas: [A university cyclotron network with shared regulatory files for new tracers](https://nuclide.cc/ideas/idea-fund-academic-radiopharma-pipeline/)
- pairings: [177Lu-PSMA-617 then 225Ac-PSMA rescue therapy](https://nuclide.cc/pairings/beta-psma-then-alpha-psma-rescue/)
- key papers: [225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-kratochwil-ac225-psma-jnm-2016/)
- roadmaps: [Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline](https://nuclide.cc/roadmaps/alpha-therapy-roadmap/), [PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha](https://nuclide.cc/roadmaps/psma-theranostics-roadmap/)

---
JSON: https://nuclide.cc/api/v1/entities/uwe-haberkorn.json